Kronos Bio LLC

Kronos Bio LLC Liabilities

Delisted

The The Liabilities of Kronos Bio LLC (KRON) as of Nov 2, 2026 is 36.78 M USD. In the previous year, The Liabilities was 54.20 M USD — a change of -32.14% (lower).

Liabilities

36.78 MUSD

YoY

-32.14%

Last updated:

In 2024, Kronos Bio LLC's total liabilities amounted to 36.78 M USD, a -32.14% difference from the 54.20 M USD total liabilities in the previous year.

The Kronos Bio LLC Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
19.91 M USD
Jan 1, 2019
125.89 M USD
Jan 1, 2020
46.45 M USD
Jan 1, 2021
46.38 M USD
Jan 1, 2022
50.44 M USD
Jan 1, 2023
54.20 M USD
Jan 1, 2024
36.78 M USD
The Kronos Bio LLC Liabilities history
YEARLiabilitiesYoY
36.78 MUSD-32.14%
54.20 MUSD+7.46%
50.44 MUSD+8.75%
46.38 MUSD-0.14%
46.45 MUSD-63.11%
125.89 MUSD+532.29%
19.91 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kronos Bio LLC Stock analysis

What does Kronos Bio LLC do? Kronos Bio Inc is a biotech company founded in 2017 by an experienced team, specialized in developing new therapeutics for cancer treatment. The company is based in Cambridge, Massachusetts and collaborates closely with leading scientific institutions. Kronos Bio Inc's business model focuses on identifying and researching new targets to develop drugs for the treatment of cancer and other diseases. The company utilizes artificial intelligence and machine learning to identify molecular mechanisms, enabling better prediction of the effectiveness of new drugs. Kronos Bio Inc is divided into different divisions, each focusing on specific therapeutic approaches. The "Transcription Regulation" division explores the control of gene expression in tumor cells and seeks potential points of intervention. The "Epigenetics" division, on the other hand, investigates how cells modify their DNA and the role this plays in the development of cancer. Another division focuses on blocking specific enzyme activities that are considered essential factors for the growth of tumor cells. Currently, Kronos Bio Inc does not offer concrete products as it is still in the development phase. However, the company has already established a number of collaborations with other companies and scientific institutions to research and further develop new drug candidates. One of the most significant partnerships is with the pharmaceutical company Gilead Sciences, which has the option to license selected drug candidates from Kronos Bio Inc as part of the collaboration. Overall, Kronos Bio has quickly made a name for itself in the biotech industry with its innovative approach and ambitious plans to develop new drugs against cancer. The company has raised several million dollars in capital and has prominent investors such as Omega Funds and Vida Ventures on board. The goal of Kronos Bio is to develop new therapies that allow for improved survival rates and a higher quality of life for cancer patients. Kronos Bio LLC is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Kronos Bio LLC's Liabilities

Kronos Bio LLC's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Kronos Bio LLC's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Kronos Bio LLC's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Kronos Bio LLC's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Kronos Bio LLC’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Kronos Bio LLC stock

The Liabilities of Kronos Bio LLC is 36.78 M USD in 2024.

The Liabilities of Kronos Bio LLC changed from 54.20 M USD to 36.78 M USD, representing a -32.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Kronos Bio LLC since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Kronos Bio LLC historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Kronos Bio LLC

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Kronos Bio LLC